The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Patients with a rare disease called mucous membrane pemphigoid are at risk of developing squamous cell carcinoma and basal cell carcinoma, finds a new study.

The B.C. government announced on Monday it is ending the program that sent some patients to the U.S. for radiation therapy. The program, which began in May 2023, offered eligible patients the ...

reducing quality of life and increasing suffering for both patients and families," Jason Krellman, a clinical neuropsychologist and assistant professor at Columbia University Irving Medical Center ...

and cemiplimab (Libtayo), an anti–PD-1 agent, in patients with advanced melanoma. 1 The first-in-human, phase 1, open-label, dose-escalation and cohort expansion trial sought to evaluate the safety ...

Notably, 27.3% (6 patients) had also failed second-line PD-1 inhibitors such as Libtayo or Keytruda. Among the enrolled patients, two advanced-stage patients achieved a progression-free survival (PFS) ...

Optimal Treatment Response: Three patients achieved partial response ... or in combination with the second-line immunotherapy Libtayo. The company aims to explore further indications and potential ...

A composer who was inspired by the sounds of her cancer treatment has created music to soothe other patients. Helen Anahita Wilson, 43, from Brighton, found inspiration in the whirring and buzzing ...